MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Viking Therapeutics Inc

Suletud

SektorTervishoid

25.59 -0.81

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

24.87

Max

26.54

Põhinäitajad

By Trading Economics

Sissetulek

-10M

-35M

Aktsiakasum

-0.32

Töötajad

36

EBITDA

-9.6M

-46M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+248.66% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

23. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-570M

2.7B

Eelmine avamishind

26.4

Eelmine sulgemishind

25.59

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

Viking Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. apr 2025, 14:14 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Viking Seen as Potential Ticket To Get Pfizer Back Into Obesity Game -- Market Talk

7. veebr 2025, 10:30 UTC

Peamised uudised

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

23. dets 2024, 15:04 UTC

Peamised uudised

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13. dets 2024, 14:53 UTC

Peamised uudised

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

4. nov 2024, 12:22 UTC

Peamised uudised

Viking Therapeutics Jumps On Latest Obesity Drug Data -- IBD

4. nov 2024, 12:00 UTC

Peamised uudised

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

4. nov 2024, 10:11 UTC

Kuumad aktsiad

Stock to Watch Monday: Trump Media, Viking Therapeutics, Nvidia, Intel -- WSJ

4. okt 2024, 12:01 UTC

Peamised uudised

As Weight-Loss Drugs Battle, Upstart Viking -2-

4. okt 2024, 12:01 UTC

Peamised uudised

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

20. sept 2024, 13:55 UTC

Peamised uudised

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

25. juuli 2024, 15:03 UTC

Tulu

Viking Stock Jumps After Company Speeds Development Its Weight-Loss Pill -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Viking Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

248.66% tõus

12 kuu keskmine prognoos

Keskmine 89.92 USD  248.66%

Kõrge 125 USD

Madal 30 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Viking Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

17 ratings

15

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

25.48 / 25.7Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.